Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Rani Therapeutics reported Q2 contract revenue of $1.7 million, driven by its collaboration with Chugai, and narrowed its net loss to $8.4 million compared to the prior year. The company announced positive initial Phase 1a data for RT-114, achieving bioavailability greater than 150% relative to subcutaneous dosing, and expanded its obesity pipeline through a new R&D collaboration with PegBio.
Key figures
- Revenue
- 1700000
- Net loss
- 8400000
- Cash position
- 53400000
- Bioavailability rt114
- >150%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.